Reported 0 shares, down 139,000 (100.0%) from the prior quarter.
Reported value -100.0%; share count -100.0% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2021-12-31 | 45000 |
| 2022-03-31 | 65000 |
| 2022-06-30 | 59000 |
| 2022-09-30 | 59000 |
| 2022-12-31 | 63678 |
| 2023-03-31 | 61559 |
| 2023-06-30 | 58936 |
| 2023-09-30 | 58200 |
| 2023-12-31 | 90675 |
| 2024-03-31 | 136484 |
| 2024-06-30 | 0 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q2 2024 | Reduced | 0 | -139,000 (-100.0%) | 0 | $0 | 2024-08-06 | |
| Q1 2024 | Added | 139,000 | +47,000 (51.1%) | < 0.01% | $136,484 | 2024-05-15 | |
| Q4 2023 | Added | 92,000 | +32,000 (53.3%) | < 0.01% | $90,675 | 2024-02-13 | |
| Q3 2023 | Unchanged | 60,000 | 0 (0.0%) | < 0.01% | $58,200 | 2023-11-14 | |
| Q2 2023 | Unchanged | 60,000 | 0 (0.0%) | < 0.01% | $58,936 | 2023-08-14 | |
| Q1 2023 | Unchanged | 60,000 | 0 (0.0%) | < 0.01% | $61,559 | 2023-05-15 | |
| Q4 2022 | Unchanged | 60,000 | 0 (0.0%) | < 0.01% | $63,678 | 2023-01-25 | |
| Q3 2022 | Unchanged | 60,000 | 0 (0.0%) | < 0.01% | $59,000 | 2022-11-02 | |
| Q2 2022 | Reduced | 60,000 | -5,000 (-7.7%) | < 0.01% | $59,000 | 2022-08-03 | |
| Q1 2022 | Added | 65,000 | +22,000 (51.2%) | < 0.01% | $65,000 | 2022-05-04 | |
| Q4 2021 | Unchanged | 43,000 | 0 (0.0%) | < 0.01% | $45,000 | 2022-03-07 | |
|
Five years are shown. A free account unlocks the complete reported history.
Unlock full history
|
|||||||
Who else reported the position
68 managers reported BIOMARIN PHARMACEUTICAL INC for Q2 2024.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| OSTERWEIS CAPITAL MANAGEMENT INC | New | 82,159,000 | +82,159,000 | 4.22% | $81,690,584 | 1 qtr |
| Sculptor Capital LP | New | 48,584,000 | +48,584,000 | 0.91% | $48,334,278 | 3 qtrs |
| MILLENNIUM MANAGEMENT LLC | Unchanged | 0 | 0 | 0.02% | $43,774,133 | 3 qtrs |
| LAZARD ASSET MANAGEMENT LLC | Added | 39,712,000 | +612,000 | 0.05% | $39,485,000 | 7 qtrs |
| Voya Investment Management LLC | Reduced | 38,250,000 | -2,290,000 | 0.04% | $38,031,924 | 8 qtrs |
| GLAZER CAPITAL LLC | Unchanged | 0 | 0 | 2.31% | $29,748,000 | 1 qtr |
| Citigroup Inc | Added | 26,484,000 | +567,000 | 0.02% | $26,266,831 | 7 qtrs |
| AVIVA PLC | Reduced | 25,000,000 | -500,000 | 0.07% | $24,755,475 | 6 qtrs |
| TENOR CAPITAL MANAGEMENT Co L P | Added | 23,693,000 | +2,031,000 | 0.37% | $23,648,082 | 3 qtrs |
| PIPER SANDLER & CO | New | 21,581,000 | +21,581,000 | 16.66% | $21,311,238 | 1 qtr |
Filing details and methodology As reported
- Report period
- June 30, 2024
- Filed
- August 06, 2024
- Filing type
- 13F-HR
- Position type
- NOTE 0.599% 8/0
Voting authority reported
No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.